Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Priority claimed from PCT/EP2002/010194external-prioritypatent/WO2003022282A1/en
Publication of MXPA04002407ApublicationCriticalpatent/MXPA04002407A/es
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Los pacientes que sufren de carcinoma renal son tratados con agentes anti-angiogenesis de 4-piridilmetil-ftalazina. Los pacientes que tienen diferentes tipos de tumor, por ejemplo, cancer renal, son tratados con un agente anti-angiogenesis de 4-piridilmetil-ftalazina mientras experimentan quimioterapia.
MXPA04002407A2001-09-122002-09-11Uso de 4-piridilmeetil-ftalazinas para el tratamiento de cancer.
MXPA04002407A
(es)